Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123425732 | 12342573 | 2 | F | 201601 | 20160505 | 20160506 | 20160830 | EXP | US-009507513-1603USA004734 | MERCK | 59.00 | YR | M | Y | 62.00000 | KG | 20160830 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123425732 | 12342573 | 1 | SS | PEMBROLIZUMAB. | PEMBROLIZUMAB | 1 | Intravenous (not otherwise specified) | 200 MG, Q3W | U | 0 | 200 | MG | SOLUTION FOR INJECTION | Q3W | |||||
| 123425732 | 12342573 | 2 | SS | PEMBROLIZUMAB. | PEMBROLIZUMAB | 1 | Intravenous (not otherwise specified) | 200 MG, Q3W | U | 0 | 200 | MG | SOLUTION FOR INJECTION | Q3W | |||||
| 123425732 | 12342573 | 3 | SS | PEMBROLIZUMAB. | PEMBROLIZUMAB | 1 | Intravenous (not otherwise specified) | 200 MG, Q3W | U | 0 | 200 | MG | SOLUTION FOR INJECTION | Q3W | |||||
| 123425732 | 12342573 | 4 | PS | POSACONAZOLE | POSACONAZOLE | 1 | UNK | U | 205053 | TABLET | |||||||||
| 123425732 | 12342573 | 5 | SS | AMBISOME | AMPHOTERICIN B | 1 | U | 0 | |||||||||||
| 123425732 | 12342573 | 6 | SS | IDELALISIB | IDELALISIB | 1 | Oral | 100 MG, ONCE DAILY | U | 0 | 100 | MG | QD | ||||||
| 123425732 | 12342573 | 7 | SS | IDELALISIB | IDELALISIB | 1 | Oral | 100 MG, BID | U | 0 | 100 | MG | BID | ||||||
| 123425732 | 12342573 | 8 | C | CANCIDAS | CASPOFUNGIN ACETATE | 1 | UNK | U | 0 | INJECTION | QD | ||||||||
| 123425732 | 12342573 | 9 | C | CEFEPIME | CEFEPIME HYDROCHLORIDE | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123425732 | 12342573 | 1 | Chronic lymphocytic leukaemia |
| 123425732 | 12342573 | 4 | Antifungal treatment |
| 123425732 | 12342573 | 5 | Fungal infection |
| 123425732 | 12342573 | 8 | Fungal infection |
| 123425732 | 12342573 | 9 | Fungal infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123425732 | 12342573 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123425732 | 12342573 | Acute kidney injury | |
| 123425732 | 12342573 | Alanine aminotransferase increased | |
| 123425732 | 12342573 | Aspartate aminotransferase increased | |
| 123425732 | 12342573 | Blood alkaline phosphatase increased | |
| 123425732 | 12342573 | Blood bilirubin increased | |
| 123425732 | 12342573 | Blood creatinine increased | |
| 123425732 | 12342573 | Diarrhoea | |
| 123425732 | 12342573 | Febrile neutropenia | |
| 123425732 | 12342573 | Hypophosphataemia | |
| 123425732 | 12342573 | Lung infection | |
| 123425732 | 12342573 | Neutrophil count decreased | |
| 123425732 | 12342573 | Platelet count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123425732 | 12342573 | 1 | 20160119 | 20160208 | 0 | |
| 123425732 | 12342573 | 2 | 20160301 | 20160301 | 0 | |
| 123425732 | 12342573 | 3 | 20160323 | 20160323 | 0 | |
| 123425732 | 12342573 | 4 | 201601 | 0 | ||
| 123425732 | 12342573 | 6 | 20160314 | 201603 | 0 | |
| 123425732 | 12342573 | 7 | 20160321 | 20160325 | 0 |